Infliximab (Remsima® subcutaneous) is indicated for treatment of adult patients with Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis in line with the adult indications of the IV formulation.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||23/09/2020|
|Rapid review completed||15/10/2020|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that Remsima SC not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.